Genovese Burford & Brothers Wealth & Retirement Plan Management LLC Has $488,000 Stake in Merck & Co., Inc. (MRK)

Genovese Burford & Brothers Wealth & Retirement Plan Management LLC reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 4.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,388 shares of the company’s stock after selling 275 shares during the quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC’s holdings in Merck & Co., Inc. were worth $488,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in MRK. Cedar Capital LLC grew its position in Merck & Co., Inc. by 8.4% during the fourth quarter. Cedar Capital LLC now owns 6,431 shares of the company’s stock valued at $491,000 after acquiring an additional 500 shares during the period. Wetherby Asset Management Inc. boosted its position in shares of Merck & Co., Inc. by 2.6% in the fourth quarter. Wetherby Asset Management Inc. now owns 95,673 shares of the company’s stock worth $7,310,000 after buying an additional 2,406 shares during the period. Eagle Global Advisors LLC boosted its position in shares of Merck & Co., Inc. by 0.3% in the fourth quarter. Eagle Global Advisors LLC now owns 159,505 shares of the company’s stock worth $12,188,000 after buying an additional 437 shares during the period. First Personal Financial Services boosted its position in shares of Merck & Co., Inc. by 118.2% in the fourth quarter. First Personal Financial Services now owns 9,182 shares of the company’s stock worth $702,000 after buying an additional 4,974 shares during the period. Finally, Focused Wealth Management Inc boosted its position in shares of Merck & Co., Inc. by 71.1% in the fourth quarter. Focused Wealth Management Inc now owns 9,393 shares of the company’s stock worth $718,000 after buying an additional 3,904 shares during the period. Hedge funds and other institutional investors own 72.55% of the company’s stock.

Shares of NYSE MRK opened at $81.57 on Monday. Merck & Co., Inc. has a 52-week low of $52.83 and a 52-week high of $82.12. The company has a market cap of $219.93 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 1.99 and a beta of 0.62. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.17.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Friday, February 1st. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a return on equity of 36.83% and a net margin of 14.71%. The firm had revenue of $11 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the firm posted $0.98 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, equities research analysts predict that Merck & Co., Inc. will post 4.65 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is 50.69%.

Several equities research analysts have recently weighed in on the company. BMO Capital Markets reaffirmed a “hold” rating on shares of Merck & Co., Inc. in a research report on Tuesday, February 19th. Argus upped their target price on Merck & Co., Inc. to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research cut Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 24th. Citigroup set a $65.00 price target on Merck & Co., Inc. and gave the stock a “hold” rating in a research note on Thursday, December 20th. Finally, Credit Suisse Group set a $86.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, December 13th. Six research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $77.06.

In other news, Chairman Kenneth C. Frazier sold 135,613 shares of the stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $80.03, for a total transaction of $10,853,108.39. Following the sale, the chairman now directly owns 784,863 shares in the company, valued at approximately $62,812,585.89. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Kenneth C. Frazier sold 231,566 shares of the stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $78.08, for a total value of $18,080,673.28. Following the sale, the chairman now owns 923,516 shares in the company, valued at $72,108,129.28. The disclosure for this sale can be found here. Insiders have sold a total of 709,324 shares of company stock worth $56,162,582 over the last quarter. Insiders own 0.32% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2019/03/18/genovese-burford-brothers-wealth-retirement-plan-management-llc-has-488000-stake-in-merck-co-inc-mrk.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.